Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

Emmanuel Bachy, MD, PhD; John F. Seymour, MBBS, PhD; Pierre Feugier, MD; Fritz Offner, MD, PhD; Armando López-Guillermo, MD; David Belada, MD, PhD; Luc Xerri, PhD, MD; John V. Catalano, MD; Pauline Brice, MD; François Lemorion, MD; Alejandro Martín, MD, PhD; Olivier Casasnovas, MD; Lars M. Pedersen, MD; Véronique Dorvaux, MD; David Simpson, MD; Sirpa Leppa, MD, PhD; Jean Gabarre, MD; Maria G. da Silva, MD, PhD; Sylvie Glaisner, MD; Loic Ysebaert, MD, PhD; Anne Vekhoff, MD; Tanin Intragumtornchai, MD; Steven Le Gouill, MD, PhD; Andrew Lister, MD; Jane A. Estell, MD; Gustavo Milone, MD; Anne Sonet, MD; Jonathan Farhi, MD; Harald Zeuner; Hervé Tilly, MD; and Gilles Salles, MD, PhD

PURPOSE The PRIMA study (ClinicalTrials.gov identifier: NCT00140582) established that 2 years of rituximab maintenance after first-line immunochemotherapy significantly improved progression-free survival (PFS) in patients with follicular lymphoma compared with observation. Here, we report the final PFS and overall survival (OS) results from the PRIMA study after 9 years of follow-up and provide a final overview of safety.

METHODS Patients (> 18 years of age) with previously untreated high–tumor-burden follicular lymphoma were nonrandomly assigned to receive one of three immunochemotherapy induction regimens. Responding patients were randomly assigned (stratified by induction regimen, response to induction treatment, treatment center, and geographic region) 1:1 to receive 2 years of rituximab maintenance (375 mg/m², once every 8 weeks), starting 8 weeks after the last induction treatment, or observation (no additional treatment). All patients in the extended follow-up provided their written informed consent (data cutoff: December 31, 2016).

RESULTS In total, 1,018 patients completed induction treatment and were randomly assigned to rituximab maintenance (n = 505) or observation (n = 513). Consent for the extended follow-up was provided by 607 patients (59.6%) of 1,018 (rituximab maintenance, n = 309; observation, n = 298). After data cutoff, median PFS was 10.5 years in the rituximab maintenance arm compared with 4.1 years in the observation arm (hazard ratio, 0.61; 95% CI, 0.52 to 0.73; P < .001). No OS difference was seen in patients randomly assigned to rituximab maintenance or observation (hazard ratio, 1.04; 95% CI, 0.77 to 1.40; P = .7948); 10-year OS estimates were approximately 80% in both study arms. No new safety signals were observed.

CONCLUSION Rituximab maintenance after induction immunochemotherapy provides a significant long-term PFS, but not OS, benefit over observation.

J Clin Oncol 37:2815-2824. © 2019 by American Society of Clinical Oncology

INTRODUCTION

Follicular lymphoma (FL) is the second most common lymphoma subtype in the United States and Western Europe, accounting for approximately 25% of all non-Hodgkin lymphoma cases and 70% of indolent lymphomas.1-3 Although the prognosis of patients with FL has significantly improved since the introduction of rituximab to first-line (1L) and salvage therapies,4-10 advanced-stage FL is believed to remain incurable in most patients because of inevitable relapses; however, strides have been made to prolong the duration of remission without exposure to additional cytotoxic treatment. Previous studies have demonstrated a significant clinical benefit for rituximab maintenance in patients with relapsed disease after induction with chemotherapy with or without rituximab9,11 or single-agent rituximab12,13 and in patients undergoing autologous stem-cell transplantation.14 Rituximab maintenance after chemotherapy15 or single-agent rituximab16 has also been studied in patients with previously untreated FL, with favorable results; however, neither of these induction regimens is considered optimal for patients with advanced-stage disease.

The pivotal PRIMA study (ClinicalTrials.gov identifier: NCT00140582) was the first phase III trial, to our knowledge, to evaluate the potential benefit of 2 years of rituximab maintenance in patients with high–tumor-burden FL responding to 1L rituximab-containing immunochemotherapy.17 After a median follow-up of 3 years, rituximab maintenance significantly
prolonged progression-free survival (PFS) compared with observation; risk of disease progression was reduced by 45% (hazard ratio [HR], 0.55; 95% CI, 0.44 to 0.68; \( P < .001 \)), and 3-year PFS rates were 74.9% and 57.6%, respectively. This PFS benefit was achieved regardless of the induction regimen, response to induction treatment, or patient age. Time to next antilymphoma treatment (TTNLT) and time to next chemotherapy treatment (TTNCT) were also significantly prolonged with rituximab maintenance, but no overall survival (OS) benefit was seen. An updated 6-year follow-up of the PRIMA study confirmed these results.18 Rituximab maintenance is now widely recommended for patients with FL responding to 1L rituximab-based immunochemotherapy.19 We present the final PFS and OS results from the PRIMA study after 9 years of follow-up and a final overview of safety.

**METHODS**

**Study Design, Patients, and Treatments**

PRIMA was an open-label, international, multicenter, randomized phase III trial in patients with previously untreated, high–tumor-burden FL. The study comprised two phases: induction and maintenance or observation (undertaken between December 2004 and April 2007, in 223 centers in 25 countries). Patients eligible for induction therapy were older than 18 years with untreated FL (histologic grade 1, 2, or 3a), diagnosed by a lymph node biopsy performed within 4 months of study registration. Inclusion and exclusion criteria are described in full elsewhere.17 During the induction phase, patients received rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP; six cycles); cyclophosphamide, vincristine, and prednisone (CVP; eight cycles); or fludarabine, cyclophosphamide, and mitoxantrone (FCM; six cycles).17 Each center selected their preferred regimen for all patients enrolled at that center. Rituximab (375 mg/m²) was administered intravenously on day 1 of each chemotherapy course. CHOP- and FCM-treated patients received two additional rituximab infusions to ensure equivalent exposure during the induction phase.

Response was assessed 2 to 4 weeks after last induction treatment. Patients achieving a complete response (CR), an unconfirmed complete response (CRu), or a partial response (PR) were eligible for the next study phase. Eligible patients must have received at least four cycles of rituximab plus CHOP, six cycles of rituximab plus CVP, or four cycles of rituximab plus FCM. At least six infusions of rituximab were required for each treatment regimen, without a delay of more than 2 weeks between each cycle. Responding patients were randomly assigned 1:1 to receive rituximab maintenance (375 mg/m², once every 8 weeks), starting 8 weeks after last induction treatment, or observation (no additional treatment). All randomly assigned patients received rituximab maintenance or underwent observation for 2 years or until disease progression, whichever occurred first. The random assignment procedure has been reported previously.12 Patients who completed this phase were initially followed for 3 years (data cutoff: January 31, 2011, per initial protocol) or 5 years (data cutoff: January 31, 2013, per protocol amendment). Patients in this extended follow-up study consented in writing to approximately 2 more years of follow-up (data cutoff: December 31, 2016).

PRIMA was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. The study protocol and amendments were approved by local and national ethics committees, according to the laws of each country. Patients provided written informed consent.

**Assessments**

Response was evaluated according to the 1999 International Working Group response criteria for non-Hodgkin lymphoma.20 During the 2-year rituximab maintenance or observation phase, patients were assessed by clinical examination every 8 weeks and had a computed tomography scan every 6 months. If bone marrow involvement was initially documented, a biopsy was required at the end-of-treatment assessment to confirm CR. Patients completing the rituximab maintenance or observation phase underwent a final restaging assessment within 28 days of the last rituximab dose (or within a corresponding timeframe for those randomly assigned to observation). For patients with no disease progression, follow-up assessments were scheduled every 3 months for the first 2 years, then every 6 months for an additional 3 years, and then annually in patients consenting to the extended follow-up. Patients with disease progression were followed annually for the initiation of new treatment and OS for 5 years, or until data cutoff in patients consenting to the extended follow-up.

**Efficacy and Safety Analyses**

The primary end point was investigator-assessed PFS. Secondary end points included TTNLT, TTNCT, OS, and transformation rate at relapse. Safety outcome measures included adverse events (AEs), serious AEs, grade 3 or higher AEs, and deaths. Grading of AEs was according to National Cancer Institute Common Terminology Criteria for Adverse Events, version 3.0.

**Statistical Analysis**

PFS was defined as the time from random assignment to progression, relapse, or death from any cause. Responding patients and patients lost to follow-up were censored at their last tumor assessment date. OS was determined from the date of random assignment to the date of death regardless of cause. Survival end points were estimated by Kaplan-Meier methodology and compared using a two-sided log-rank test stratified by induction regimen and induction response. Histologic transformation rates at first relapse were compared using a \( \chi^2 \) test.
RESULTS

Patients

Overall, 1,018 patients completed induction treatment and were randomly assigned to rituximab maintenance (n = 505) or observation (n = 513); these patients were the primary population for efficacy analyses. Nine patients (rituximab maintenance, n = 4; observation, n = 5) withdrew before the first maintenance treatment cycle or observation visit and were excluded from the safety analyses. Consent for the extended follow-up was provided by 607 patients (59.6%) of 1,018 (rituximab maintenance, n = 309; observation, n = 298). An overview of the trial profile is provided in Figure 1. Median duration of follow-up was 9.0 years (range, 0.0 to 11.5 years) from random assignment and was well balanced between arms (rituximab maintenance, 9.1 years; observation, 9.0 years). Patient demographics and disease characteristics at random assignment are listed in Table 1. Patients not included in the extended follow-up exhibited adverse prognostic factors more frequently than those in the extended follow-up, mainly because of the automatic exclusion of patients who died before the current analysis [data not shown].

Efficacy

Rituximab maintenance after rituximab-containing induction immunochemotherapy continued to provide a significant long-term PFS benefit compared with observation (Table 2; Fig 2A). At the final data cutoff, median PFS was 10.5 years in patients randomly assigned to rituximab

---

FIG 1. CONSORT diagram. Full details of the trial profile before follow-up have been published previously.\(^\text{17}\) CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP, cyclophosphamide, vincristine, and prednisone; FCM, fludarabine, cyclophosphamide, and mitoxantrone; ITT, intent-to-treat.
maintenance versus 4.1 years in patients randomly assigned to observation (HR, 0.61; 95% CI, 0.52 to 0.73; \( P < .001 \)). Ten-year PFS estimates were 51.1% in the rituximab maintenance arm and 35.0% in the observation arm. Evaluation of PFS in prespecified patient subgroups, categorized by age, sex, FLIPI score, induction chemotherapy, and response to induction, showed a consistent benefit of rituximab maintenance over observation (Fig 3).

Patients in CR, CRu, or PR at end of induction consistently benefited from rituximab maintenance (Data Supplement). PFS by FLIPI risk factor category in the two treatment arms is shown in the Data Supplement.

Rituximab maintenance also provided a significant benefit over observation in terms of time to next treatment; median TTNLT was not reached in the rituximab maintenance arm versus 6.1 years in the observation arm (HR, 0.66; 95% CI, 0.55 to 0.78; \( P < .001 \); Table 2; Fig 2B). At the final data cutoff, 212 patients (42.0%) of 505 in the rituximab maintenance arm and 284 patients (55.4%) of 513 in the observation arm had either started a new antilymphoma treatment or died before receiving it. Ten-year TTNLT estimates were 53.4% in the rituximab maintenance arm and 41.2% in the observation arm.

Median TTNCT was not reached in the rituximab maintenance arm versus 9.3 years in the observation arm (HR, 0.71; 95% CI, 0.59 to 0.86; \( P < .001 \); Table 2; Fig 2C); at data cutoff, 188 patients (37.2%) of 505 in the rituximab maintenance arm and 244 patients

### TABLE 1. Baseline Patient Demographics and Disease Characteristics (MITT, extended follow-up population, and no extended follow-up population)

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Randomly Assigned</th>
<th>Extended Follow-Up</th>
<th>No Extended Follow-Up</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Observation (n = 513)</td>
<td>Rituximab Maintenance (n = 505)</td>
<td>Observation (n = 298)</td>
</tr>
<tr>
<td>Age &gt; 60 years</td>
<td>180 (35.1)</td>
<td>176 (34.9)</td>
<td>91 (30.5)</td>
</tr>
<tr>
<td>Median age, years (range)</td>
<td>55 (22-84)</td>
<td>57 (26-79)</td>
<td>54 (27-80)</td>
</tr>
<tr>
<td>Sex, male</td>
<td>263 (51.2)</td>
<td>270 (53.5)</td>
<td>147 (49.3)</td>
</tr>
<tr>
<td>Ann Arbor stage III or IV</td>
<td>459 (89.5)</td>
<td>459 (90.9)</td>
<td>266 (89.3)</td>
</tr>
<tr>
<td>ECOG PS ≥ 1</td>
<td>172 (33.5)</td>
<td>181 (35.8)</td>
<td>88 (29.5)</td>
</tr>
<tr>
<td>“B” symptoms present</td>
<td>156 (30.4)</td>
<td>160 (31.7)</td>
<td>76 (25.5)</td>
</tr>
<tr>
<td>Bone marrow involvement</td>
<td>285 (55.6)</td>
<td>275 (54.5)</td>
<td>163 (54.7)</td>
</tr>
<tr>
<td>Lactate dehydrogenase &gt; ULN</td>
<td>164 (32.0)</td>
<td>173 (34.3)</td>
<td>83 (27.9)</td>
</tr>
<tr>
<td>Hemoglobin &lt; 120 g/L</td>
<td>96 (18.7)</td>
<td>100 (19.8)</td>
<td>45 (15.1)</td>
</tr>
<tr>
<td>β2-microglobulin ≥ 3 mg/L</td>
<td>132 (27.8)</td>
<td>148 (31.6)</td>
<td>69 (25.2)</td>
</tr>
<tr>
<td>FLIPI score</td>
<td>Low (0-1 risk factors)</td>
<td>110 (21.4)</td>
<td>106 (21.0)</td>
</tr>
<tr>
<td>Intermediate (2 risk factors)</td>
<td>187 (36.5)</td>
<td>183 (36.2)</td>
<td>116 (38.9)</td>
</tr>
<tr>
<td>High (3-5 risk factors)</td>
<td>216 (42.1)</td>
<td>215 (42.6)</td>
<td>109 (36.6)</td>
</tr>
<tr>
<td>Induction regimen</td>
<td>Rituximab plus CHOP</td>
<td>386 (75.2)</td>
<td>382 (75.6)</td>
</tr>
<tr>
<td>Rituximab plus CVP</td>
<td>113 (22.0)</td>
<td>109 (21.6)</td>
<td>56 (18.8)</td>
</tr>
<tr>
<td>Rituximab plus FCM</td>
<td>14 (2.7)</td>
<td>14 (2.8)</td>
<td>12 (4.0)</td>
</tr>
</tbody>
</table>

Data are No. (%) unless otherwise specified.

Abbreviations: CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CVP, cyclophosphamide, vincristine, and prednisone; ECOG PS, Eastern Cooperative Oncology Group performance status; FCM, fludarabine, cyclophosphamide, and mitoxantrone; FLIPI, Follicular Lymphoma International Prognostic Index; MITT, maintenance intent-to-treat; ULN, upper limit of normal.

*Data missing in five patients.
*Data missing in one patient.
*Data missing in two patients.
*Data missing in 38 patients.
*Data missing in 37 patients.
*Data missing in 24 patients.
*Data missing in 18 patients.
*Data missing in 14 patients.
*Data missing in 19 patients.
*FLIPI scores were collected at registration (risk score includes five factors: age [> 60 years], Ann Arbor stage [III or IV], hemoglobin [< 120 g/L], serum lactate dehydrogenase [> ULN], and number of nodal areas involved [five or more]).
(47.6%) of 513 in the observation arm had either started a new chemotherapy treatment or had died before receiving it. The above-mentioned beneficial effects of rituximab maintenance did not translate into an OS benefit (Table 2, Fig 2D), with 10-year OS rate estimates of approximately 80% (observation, 79.9%; rituximab maintenance, 80.1%) in both study arms; median OS was not reached in either arm (HR, 1.04; 95% CI, 0.77 to 1.40; P = .7948). OS according to FLIPI risk factor categories in patients randomly assigned to rituximab maintenance or observation is shown in the Data Supplement. OS after progression or relapse (ie, time from first progression until death) was shorter in the maintenance arm versus the observation arm, explaining equivalent OS in both arms (Data Supplement).

A total of 503 patients had documented disease progression. The rate of progression with disease transformation was low, but similar in both study arms (Data Supplement). No difference in time to transformation was observed (Data Supplement).

**Second-Line Treatment**

Of 503 patients who experienced disease progression, 453 received documented second-line (2L) therapy. The most common subsequent chemotherapy regimens were rituximab with a platinum-based regimen (27.2%), fludarabine-based regimen (12.1%), or bendamustine (8.6%; Data Supplement). Significantly more patients in the observation arm than in the rituximab maintenance arm received a rituximab-containing therapy at relapse or progression (81.5% vs 73.2%, respectively; P = .04). Slightly more patients in the observation arm received radioimmunotherapy (24.4% vs 16.9%, respectively; P = .06). One hundred twenty patients (26.5%) underwent high-dose therapy followed by autologous stem-cell transplantation with no difference between the two arms (29.3% vs 22.4%, respectively; P = .13). Response to 2L regimen was similar between 1L treatment arms, with overall response and CR rates of 78.2% and 47.3%, respectively (rituximab maintenance) versus 80.4% and 46.4%, respectively (observation). However, the rate of CR/CRu for patients who experienced early progression within 18 months of random assignment (corresponding to 24 months after induction) was inferior in the maintenance arm compared with the observation arm (39.3% vs 56.3%; P = 0.029), thus demonstrating that the patients who experienced disease progression during maintenance were those with a more aggressive disease (Data Supplement).

**Safety**

Since random assignment, 285 patients (56.9%) of 501 in the rituximab maintenance arm and 194 patients (38.2%) of 508 in the observation arm have experienced at least one AE (Data Supplement). Rituximab maintenance was associated with a higher rate of grade 3 to 4 AEs (24.4% vs 16.9%, respectively; P = .06). One hundred twenty patients (26.5%) underwent high-dose therapy followed by autologous stem-cell transplantation with no difference between the two arms (29.3% vs 22.4%, respectively; P = .13). Response to 2L regimen was similar between 1L treatment arms, with overall response and CR rates of 78.2% and 47.3%, respectively (rituximab maintenance) versus 80.4% and 46.4%, respectively (observation). However, the rate of CR/CRu for patients who experienced early progression within 18 months of random assignment (corresponding to 24 months after induction) was inferior in the maintenance arm compared with the observation arm (39.3% vs 56.3%; P = 0.029), thus demonstrating that the patients who experienced disease progression during maintenance were those with a more aggressive disease (Data Supplement).

**Table 2.** Overview of Key Efficacy Results After 6 and 9 Years of Follow-Up From Random Assignment

<table>
<thead>
<tr>
<th>Efficacy Result, years</th>
<th>Observation (n = 513)</th>
<th>Rituximab Maintenance (n = 505)</th>
<th>Observation (n = 513)</th>
<th>Rituximab Maintenance (n = 505)</th>
</tr>
</thead>
<tbody>
<tr>
<td>PFS</td>
<td>Median 4.1</td>
<td>NR</td>
<td>4.1</td>
<td>10.5</td>
</tr>
<tr>
<td>HR (95% CI), P</td>
<td>0.58 (0.48 to 0.69), &lt; .001</td>
<td>0.61 (0.52 to 0.73), &lt; .001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TTNLT</td>
<td>Median 5.9</td>
<td>NR</td>
<td>6.1</td>
<td>NR</td>
</tr>
<tr>
<td>HR (95% CI), P</td>
<td>0.63 (0.52 to 0.76), &lt; .001</td>
<td>0.66 (0.55 to 0.78), &lt; .001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TTNCT</td>
<td>Median 7.1</td>
<td>NR</td>
<td>9.3</td>
<td>NR</td>
</tr>
<tr>
<td>HR (95% CI), P</td>
<td>0.70 (0.57 to 0.86), &lt; .001</td>
<td>0.71 (0.59 to 0.86), &lt; .001</td>
<td></td>
<td></td>
</tr>
<tr>
<td>OS</td>
<td>Median NR</td>
<td>NR</td>
<td>NR</td>
<td>NR</td>
</tr>
<tr>
<td>HR (95% CI), P</td>
<td>1.02 (0.71 to 1.47), .8959</td>
<td>1.04 (0.77 to 1.40), .7948</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: HR, hazard ratio; NR, not reached; OS, overall survival; PFS, progression-free survival; TTNCT, time to next chemotherapy treatment; TTNLT, time to next antilymphoma treatment.
AEs occurred in eight patients (1.6%) of 501 and three patients (0.6%) of 508 randomly assigned to rituximab maintenance and observation, respectively (Data Supplement).

A total of 88 patients (17.4%) have died in the rituximab maintenance arm since random assignment versus 84 (16.4%) in the observation arm (Table 3). The most frequent causes of death were progressive disease (rituximab

<table>
<thead>
<tr>
<th>Category</th>
<th>Subgroup</th>
<th>No.</th>
<th>HR</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>FLIPI</td>
<td>FLIPI ≤ 1</td>
<td>624</td>
<td>0.55</td>
<td>0.44 to 0.69</td>
</tr>
<tr>
<td></td>
<td>FLIPI = 2</td>
<td>394</td>
<td>0.72</td>
<td>0.55 to 0.94</td>
</tr>
<tr>
<td></td>
<td>FLIPI ≥ 3</td>
<td>485</td>
<td>0.74</td>
<td>0.57 to 0.96</td>
</tr>
<tr>
<td></td>
<td>Male</td>
<td>533</td>
<td>0.51</td>
<td>0.41 to 0.64</td>
</tr>
<tr>
<td>Age, years</td>
<td>&lt; 60</td>
<td>216</td>
<td>0.53</td>
<td>0.34 to 0.84</td>
</tr>
<tr>
<td></td>
<td>≥ 60</td>
<td>370</td>
<td>0.51</td>
<td>0.38 to 0.69</td>
</tr>
<tr>
<td>Sex</td>
<td>Male</td>
<td>431</td>
<td>0.71</td>
<td>0.58 to 0.91</td>
</tr>
<tr>
<td></td>
<td>Female</td>
<td>768</td>
<td>0.57</td>
<td>0.47 to 0.70</td>
</tr>
<tr>
<td></td>
<td>CR/CRu</td>
<td>222</td>
<td>0.75</td>
<td>0.53 to 1.07</td>
</tr>
<tr>
<td></td>
<td>PR</td>
<td>28</td>
<td>0.58</td>
<td>0.18 to 2.07</td>
</tr>
<tr>
<td>Induction</td>
<td>Rituximab plus</td>
<td>720</td>
<td>0.64</td>
<td>0.52 to 0.79</td>
</tr>
<tr>
<td></td>
<td>CHOP chemotherapy</td>
<td>291</td>
<td>0.54</td>
<td>0.40 to 0.74</td>
</tr>
<tr>
<td></td>
<td>Rituximab plus</td>
<td>355</td>
<td>0.61</td>
<td>0.52 to 0.73</td>
</tr>
<tr>
<td></td>
<td>CVP</td>
<td>362</td>
<td>0.72</td>
<td>0.55 to 0.94</td>
</tr>
<tr>
<td></td>
<td>FCM</td>
<td>420</td>
<td>0.51</td>
<td>0.41 to 0.64</td>
</tr>
</tbody>
</table>

FIG 3. Risk of progression according to prespecified subgroups. CHOP, cyclophosphamide, doxorubicin, vincristine, and prednisone; CR, complete response; CVP, cyclophosphamide, vincristine, and prednisone; FCM, fludarabine, cyclophosphamide, and mitoxantrone; FLIPI, Follicular Lymphoma International Prognostic Index; HR, hazard ratio; PR, partial response; CRu, unconfirmed complete response.

A total of 88 patients (17.4%) have died in the rituximab maintenance arm since random assignment versus 84 (16.4%) in the observation arm (Table 3). The most frequent causes of death were progressive disease (rituximab...
maintenance, 51.1%; observation, 47.6%) and solid tumors (rituximab maintenance, 5.7%; observation, 20.2%).

**DISCUSSION**

The primary analysis from PRIMA demonstrated prolonged PFS with rituximab maintenance when applied after 1L immunochemotherapy induction to patients with previously untreated, high–tumor-burden FL. This long-term follow-up strengthens these previously published results, demonstrating significantly longer PFS, TTNLT, and TTNT in the rituximab maintenance arm compared with the observation arm. With an updated 9-year median follow-up, projected 10-year PFS was 51.1% in the rituximab maintenance arm and 35.0% in the observation arm, whereas 10-year TTNLT estimates were 53.4% and 41.2%, respectively. Clinically, these results mean that approximately half of patients who receive rituximab maintenance every 8 weeks for 2 years after response to immunochemotherapy induction will remain free from progression or death and free from further anti-lymphoma treatment after 10 years. Subgroup analyses showed the substantial PFS improvement associated with rituximab maintenance was independent of age, sex, induction immunochemotherapy regimen, response to induction (CR/CRu, or PR), or FLIPI risk score.

The OS estimate at 10 years for the whole patient cohort was approximately 80%, thus confirming how the introduction of rituximab into the therapeutic armamentarium in general, and into the 1L induction setting in particular, has profoundly altered the course of FL, as compared with historical controls. However, despite significant and sustained PFS prolongation with rituximab maintenance, no OS difference was observed between the two arms. This finding is similar to recently published long-term follow-up studies in which prolonged PFS with the use of rituximab plus CHOP (compared with rituximab plus CVP) or rituximab plus bendamustine (compared with rituximab plus CHOP) fails to translate into prolonged OS and has important implications for both our understanding of the disease and future research in the field. First, direct extrapolation of PFS as a surrogate marker for OS cannot be made in FL, even with long-term follow-up. Second, PFS and TTNLT prolongation as meaningful clinical and economic end points must be viewed independently of OS. And third, the underlying biologic explanation for PFS improvement not translating into longer OS needs to be addressed.

Recent efforts have been made by the Follicular Lymphoma Analysis of Surrogacy Hypothesis (Analysis of Surrogacy Hypothesis) group to assess if CR at 30 months after initiation of induction therapy can serve as a surrogate end point for PFS in FL, and the initial results look promising. However, the evidence for PFS as a surrogate for OS is conflicting. In advanced solid tumors, there is considerable heterogeneity among cancer types and, for a given neoplasm, there are even discrepancies among the same histology subgroups, resulting in a generally low strength of association between PFS and OS. In lymphoma, surrogacy has been studied and documented in 1L diffuse large B-cell lymphoma, but robust data are lacking in FL. Indeed, statistical modeling indicates that the association between PFS and OS tends to be weaker for malignancies with a long survival after progression, such as FL, which explains how the PFS advantage reported here may have been diluted over subsequent lines of treatment. Whether the recently

**TABLE 3. Cause of Death**

<table>
<thead>
<tr>
<th>Cause of Death</th>
<th>Observation (n = 513)</th>
<th>Rituximab Maintenance (n = 505)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total deaths, No.</td>
<td>84</td>
<td>88</td>
</tr>
<tr>
<td>Lymphoma progression</td>
<td>40 (47.6)</td>
<td>45 (51.1)</td>
</tr>
<tr>
<td>Solid tumor*</td>
<td>17 (20.2)</td>
<td>5 (5.7)</td>
</tr>
<tr>
<td>Infection†</td>
<td>5 (6.0)</td>
<td>11 (12.5)</td>
</tr>
<tr>
<td>AML/MDS</td>
<td>7 (8.3)</td>
<td>4 (4.6)</td>
</tr>
<tr>
<td>Cardiovascular event</td>
<td>5 (6.0)</td>
<td>9 (10.2)</td>
</tr>
<tr>
<td>Direct toxicity during subsequent treatment†</td>
<td>1 (1.2)</td>
<td>3 (3.4)</td>
</tr>
<tr>
<td>Other cause</td>
<td>3 (3.6)</td>
<td>6 (6.8)</td>
</tr>
<tr>
<td>Unevaluable event</td>
<td>6 (7.1)</td>
<td>5 (5.7)</td>
</tr>
</tbody>
</table>

Data presented as No. (%) unless otherwise noted.

Abbreviations: AML, acute myeloid leukemia; MDS, myelodysplastic syndrome.

*Solid tumors in the observation arm: lung cancer (n = 3), melanoma (n = 2), neuroendocrine carcinoma of the skin (n = 1), ovarian cancer (n = 2), malignant astrocytoma (n = 1), glioblastoma (n = 1), hepatocellular carcinoma (n = 1), metastatic neoplasm of unknown origin (n = 1), prostate cancer (n = 1), rectal adenocarcinoma (n = 1), salivary gland cancer (n = 1), tongue neoplasm (n = 1), cancer without precision (n = 1); solid tumors in the maintenance arm: lung cancer (n = 2), neuroendocrine carcinoma of the skin (n = 1), hepatocellular carcinoma (n = 1), and anal carcinoma (n = 1).

†Progressive multifocal leukoencephalopathy: one in each arm.

‡Toxicity during allogeneic stem-cell transplantation (n = 3) and idelalisib treatment (n = 1).
described progression of disease within 24 months of initiating treatment end point is a more reliable surrogate of OS in patients with FL receiving 1L immunochemotherapy with or without maintenance remains to be established.\textsuperscript{29–32}

In our analysis, the proportion of deaths associated with lymphoma progression was almost identical between treatment arms. Response to 2L treatment was also comparable. Shorter survival after first relapse in the maintenance arm helps to explain why OS was similar in both arms despite prolonged PFS. Altogether, these data indicate that rituximab maintenance does not alter the natural course of the disease for patients with aggressive FL and that they will ultimately die as rapidly as if they were observed after induction treatment. Whether the absence of an OS benefit in these patients challenges the appeal of a prolonged 1L remission in most patients with de novo FL with a high tumor burden remains an open question.

No difference in terms of transformation rate was found with this extended follow-up, and these findings confirmed a previous analysis of data from the PRIMA cohort, which showed that rituximab maintenance did not have a significant prognostic impact on histologic transformation.\textsuperscript{33} Interestingly, detailed analysis of 2L treatments at relapse showed that use of rituximab was significantly less frequent after rituximab maintenance than after observation. Data on the use of anti-CD20 antibodies as maintenance at relapse were lacking, but one could hypothesize that rituximab maintenance may have been more frequently administered in the observation arm, given the established beneficial effect of rituximab maintenance on PFS in the relapsed/resistant setting.\textsuperscript{34} This could potentially explain, at least in part, the absence of a difference in OS between the two arms.

Consistent with previous analyses,\textsuperscript{17,18} rituximab maintenance was generally well tolerated, and no unexpected safety signals were observed with the additional 4 years of follow-up. It is worth noting that although the OS rate was not different between the two arms, death due to second neoplasia was almost four times more frequent in the observation arm compared with the maintenance arm. It could be speculated that recurrent use of cytotoxic- and radiation-containing regimens in the context of earlier relapse in the observation arm may have increased the frequency of second neoplasms. Conversely, deaths due to infection, a known consequence of immunotherapy,\textsuperscript{34} were twice as frequent in the rituximab maintenance arm. However, only two cases of the opportunistic infection, progressive multifocal leukoencephalopathy, were observed, one in each treatment arm. Although rituximab exposure may increase this risk,\textsuperscript{35} our data suggest there is not a strong effect of maintenance.

In conclusion, this 9-year follow-up of the PRIMA study demonstrates that rituximab maintenance after induction immunochemotherapy provides a significant long-term PFS benefit over observation. Despite the lack of OS advantage, it is noteworthy that more than half of the patients in the rituximab maintenance arm remain free of disease progression and have not required new antilymphoma treatment beyond 10 years.

\textbf{AFFILIATIONS}
\begin{itemize}
  \item 1Hospices Civils de Lyon, Université Claude Bernard Lyon 1, Institut National de la Santé et de la Recherche Médicale (INSERM) 1052, Pierre-Bénite, France
  \item 2Royal Melbourne Hospital and University of Melbourne, Melbourne, Victoria, Australia
  \item 3Centre Hospitalier Régional Universitaire de Nancy, Université de Lorraine, INSERM 1256, Nancy, France
  \item 4Ghent University, Ghent, Belgium
  \item 5Hospital Clinic, Barcelona, Spain
  \item 6Charles University, Hradec Králové, Czech Republic
  \item 7Institut Paoli-Calmettes, Aix-Marseille Université, Marseille, France
  \item 8Frankston Hospital and Monash University, Frankston, Victoria, Australia
  \item 9Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris, Paris, France
  \item 10Hôpitaux Universitaires Henri Mondor, Université Paris-Est Créteil, INSERM U955, Créteil, France
  \item 11Hospital Universitario de Salamanca–Institute for Biomedical Research of Salamanca, Centro de Investigación Biomédica en Red de Cáncer, Salamanca, Spain
  \item 12Department of Haematology and INSERM 1231, University Hospital F. Mitterrand, Dijon, France
  \item 13Herlev University Hospital, Copenhagen, Denmark
  \item 14Hôpital de Mercy Centre Hospitalier Régional Metz-Thionville, Metz, France
  \item 15North Shore Hospital, Auckland, New Zealand
  \item 16Helsinki University Hospital, University of Helsinki, Helsinki, Finland
  \item 17Hôpital Pitié-Salpêtrière, Paris, France
  \item 18Portuguese Institute of Oncology, Lisbon, Portugal
  \item 19Institut Curie–Hôpital Rene Huguenin, Saint-Cloud, France
  \item 20Institut Universitaire du Cancer de Toulouse–Oncopole, Toulouse, France
  \item 21Saint Antoine Hospital, Assistance Publique–Hôpitaux de Paris, Paris, France
  \item 22Chulalongkorn University, Bangkok, Thailand
  \item 23Centre Hospitalier Universitaire de Nantes, Centre de Recherche en Cancérologie et Immunologie Nantes Angers, INSERM, Université de Nantes, Nantes, France
  \item 24Queen Mary University of London, London, United Kingdom
  \item 25Concord Hospital, Concord, University of Sydney, New South Wales, Australia
  \item 26Fundaleu, Buenos Aires, Argentina
  \item 27UCL, Mont-Godinne, Yvoir, Belgium
  \item 28Centre Hospitalier Universitaire d’Angers, Angers, France
  \item 29F Hoffman-La Roche, Basel, Switzerland
  \item 30Centre Henri-Becquerel, Rouen, France
\end{itemize}

\textbf{CORRESPONDING AUTHOR}
Emmanuel Bachy, Hematology Department, Lyon Sud Hospital, chemin du Grand Revoyet, Pierre Bénite Cedex, 69495, France; Twitter: @LysaLymphoma; e-mail: emmanuel.bachy@chu-lyon.fr.

\textbf{PRIOR PRESENTATION}
Presented in part at the American Society of Hematology Annual Meeting and Exposition, Atlanta, GA, December 9-12, 2017.
Sustained PFS After 2 Years of Rituximab Maintenance Therapy

REFERENCES

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Sustained Progression-Free Survival Benefit of Rituximab Maintenance in Patients With Follicular Lymphoma: Long-Term Results of the PRIMA Study

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO’s conflict of interest policy, please refer to www.asco.org/ncn or ascopubs.org/jco/site/ic.

Emmanuel Bachy
Honoria: Gilead Sciences, Roche, Amgen, Janssen-Cilag
Consulting or Advisory Role: Roche
Travel, Accommodations, Expenses: Janssen-Cilag

John F. Seymour
Honoria: AbbVie, Acerta Pharma, Janssen, Roche, Sunesis Pharmaceuticals, Takeda
Consulting or Advisory Role: AbbVie, Acerta Pharma, Janssen, Roche, Sunesis Pharmaceuticals, Takeda
Speakers’ Bureau: AbbVie, Celgene, Roche
Research Funding: AbbVie, Celgene, Janssen, Roche
Expert Testimony: Roche
Travel, Accommodations, Expenses: AbbVie, Roche

Pierre Feugier
Honoria: Genentech, Janssen, Gilead, Amgen, AbbVie
Research Funding: Genentech, Gilead, Janssen, AbbVie, Amgen
Travel, Accommodations, Expenses: Amgen, Gilead, Janssen, Genentech, AbbVie

Armando López-Guillermo
Consulting or Advisory Role: Roche, Celgene, Gilead/Kite Pharma, Takeda, Janssen, Incyte
Research Funding: Roche (Inst), Gilead Sciences, Celgene (Inst)
Travel, Accommodations, Expenses: Roche

David Belada
Consulting or Advisory Role: Roche, Gilead Sciences, Janssen-Cilag, Takeda
Research Funding: Roche (Inst), Gilead Sciences (Inst), Janssen-Cilag (Inst), Takeda (Inst), MorphoSys (Inst), Pharmacyclics (Inst), Archigen Biotech (Inst)
Travel, Accommodations, Expenses: Gilead Sciences, Takeda, Roche

John V. Catalano
Travel, Accommodations, Expenses: Celgene

Pauline Brice
Research Funding: Takeda, Bristol-Myers Squibb
Travel, Accommodations, Expenses: Roche, Amgen, AbbVie/Genentech

François Lemonnier
Consulting or Advisory Role: Miltenyi Biotec
Travel, Accommodations, Expenses: Janssen

Alejandro Martin
Honoria: Roche, Janssen-Cilag, Celgene, SERVIER, Gilead Sciences
Consulting or Advisory Role: Roche, Celgene, MorphoSys, Kyowa Hakko Kirin
Research Funding: Celgene, Teva, Janssen-Cilag
Expert Testimony: Gilead Sciences
Travel, Accommodations, Expenses: Roche, Celgene, SERVIER

Olivier Casasnovas
Honoria: Genentech, Takeda, Gilead Sciences, Bristol-Myers Squibb, Merck, AbbVie, Celgene, Janssen
Consulting or Advisory Role: Genentech, Takeda, Gilead Sciences, Bristol-Myers Squibb, Merck, AbbVie, Celgene, Janssen
Research Funding: Genentech (Inst), Gilead Sciences (Inst), Takeda (Inst)
Travel, Accommodations, Expenses: Genentech, Takeda, Gilead Sciences, Janssen

Véronique Dorvaux
Honoria: Takeda
Consulting or Advisory Role: Takeda
Travel, Accommodations, Expenses: Janssen Oncology

David Simpson
Honoria: Celgene, AbbVie, Janssen-Cilag, Roche, Merck Sharp & Dohme
Consulting or Advisory Role: Celgene, Merck, AbbVie, Janssen-Cilag
Research Funding: Amgen, BeIGene (Inst), Sanofi (Inst), Roche (Inst), Genentech (Kline) (Inst), Acerta Pharma (Inst), Pharmacyclics (Inst), AbbVie (Inst)
Travel, Accommodations, Expenses: Celgene, Gilead Sciences, Janssen

Sirpa Leppa
Honoria: Takeda
Consulting or Advisory Role: Novartis, Celgene, Takeda, Roche, MSD
Research Funding: Roche (Inst), Janssen-Cilag (Inst), Bayer (Inst), Celgene (Inst)

Maria G. da Silva
Consulting or Advisory Role: Janssen-Cilag, Gilead Sciences, Roche (Inst), Janssen-Cilag (Inst)
Speakers’ Bureau: Janssen-Cilag, Takeda
Research Funding: Gilead Sciences
Travel, Accommodations, Expenses: Roche, Celgene, Janssen-Cilag, Gilead Sciences, Takeda

Loïc Ysebaert
Consulting or Advisory Role: AbbVie, Janssen-Cilag, Roche, Gilead Sciences, Roche (Inst), Janssen-Cilag (Inst), Gilead Sciences (Inst)

Steven Le Gouill
Honoria: Genentech
Consulting or Advisory Role: Genentech
Research Funding: Genentech
Travel, Accommodations, Expenses: Genentech

Andrew Lister
Stock and Other Ownership Interests: AstraZeneca, GalactoSmithKline, AbbVie, Johnson & Johnson, Pfizer, AstraZeneca (I), Dechra Pharmaceuticals (I), Hirok Pharmaceuticals (I)
Consulting or Advisory Role: Genentech (DMC), Gilead Sciences, Millennium, Merck
Travel, Accommodations, Expenses: Genentech, Gilead Sciences, Takeda, Merck

Jane A. Estel
Consulting or Advisory Role: Celgene
Research Funding: AbbVie

Gustavo Milone
Honoria: mAbxience, Gador, Elea
Consulting or Advisory Role: Teva
Travel, Accommodations, Expenses: Elea, Gador, Raffo

Jonathan Farhi
Honoria: Novartis
Travel, Accommodations, Expenses: Bristol-Myers Squibb, Pfizer, Sandoz, Roche

Harald Zeuner
Employment: Hoffman-LaRoche AG

Hervé Tilly
Honoria: Bristol-Myers Squibb, SERVIER
Consulting or Advisory Role: Karyopharm Therapeutics, Roche, Janssen
Travel, Accommodations, Expenses: Roche

Gilles Salles
Honoria: Genentech, Amgen, Janssen, Celgene, SERVIER Gilead Sciences, Novartis, AbbVie, Merck, Takeda, MorphoSys
Consulting or Advisory Role: Genentech, Gilead Sciences, Janssen, Celgene, Novartis, Merck, Pfizer, Acerta Pharma, Kite Pharma, SERVIER, Morphosys, Epizyme
No other potential conflicts of interest were reported.